Schizophrenia News

Individuals with mental disorders were at increased risk for suicide, according to results of a systematic review and meta-regression analysis published in Journal of Psychiatric Research.

A novel glycine transporter inhibitor improved cognition after 12 weeks among individuals with schizophrenia, according to results of a double-blind, randomized, placebo-controlled phase 2 study published in The Lancet Psychiatry.

The presence of metabolic disorders appeared significantly linked to cognitive deficits among individuals with schizophrenia, according to results of a systematic review and meta-analysis published in JAMA Psychiatry.

Long-acting injectable formulations of paliperidone, aripiprazole and olanzapine had the highest effect sizes and certainty of evidence for relapse prevention and acceptability, researchers noted in American Journal of Psychiatry.

Childhood ADHD appeared linked to increased risk for a subsequent psychotic disorder, according to results of a systematic review and meta-analysis published in JAMA Psychiatry.

Duration of untreated psychosis may serve as an important prognostic factor at first presentation, as well as predict clinically relevant outcomes over the course of illness, according to study results published in World Psychiatry.

Baseline variables not routinely assessed and targeted by intervention programs in community mental health services were linked to functional outcomes at follow-up for schizophrenia, according to study results published in JAMA Psychiatry.

Schizophrenia spectrum disorder diagnosis appeared to be a significant risk factor for mortality among individuals with COVID-19, according to results of a retrospective cohort study published in JAMA Psychiatry.

Clozapine appeared to be the optimal treatment for violent schizophrenia patients with conduct disorder, according to study results published in American Journal of Psychiatry.

Schizophrenia spectrum disorder was linked to an increased risk for Parkinson’s disease later in life, according to study results published in Movement Disorders.